<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84011">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01954849</url>
  </required_header>
  <id_info>
    <org_study_id>LG-001</org_study_id>
    <secondary_id>185428</secondary_id>
    <secondary_id>TPS 11235</secondary_id>
    <nct_id>NCT01954849</nct_id>
  </id_info>
  <brief_title>Assessment of a Probiotic to Treat Pediatric Gingivitis</brief_title>
  <official_title>Assessment of Therapeutic Potential of a Novel Dental Probiotic in Pediatric Patients Affected by Gingivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integra Medical Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ontario Centres of Excellence</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy of a probiotic formulation (Lorodent) of 6 strains of
      bacteria (Streptococcus salivarius K12, Lactobacillus paracasei Lpc-37, L. plantarum Lp2001,
      L. salivarius Ls-33, L. acidophilus La-14, and L. reuteri Lru-1038),in reducing the
      inflammation and gingivitis in subjects between the ages of 8-14 years. Patients diagnosed
      with mild to moderate gingivitis based on a gingival index score will be recruited and
      receive a daily dose of the probiotic formulation following brushing or a placebo control
      for 30 days. They will be assessed for a gingivitis score, gum bleeding score, plaque score,
      their periodontal health  and for precarious areas 14 days throughout a 28 day treatment and
      for a 28 day post treatment period. Additionally plaque and salvia samples will be analyzed
      for changes in microbial pathogens or inflammatory cytokines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in gingivitis</measure>
    <time_frame>14, 28, 42 and 56 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gingivitis will be assessed by gingival index:
0 Normal gingival
Mild inflammation: slight change in color and slight edema and glazing;    bleeding on probing
Moderate inflammation: redness, edema and glazing; bleeding on    probing
Severe inflammation: marked redness and edema, ulceration; tendency   to spontaneous bleeding.
Significant reduction or change in any of these categories over time will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduced plaque</measure>
    <time_frame>14, 28, 42 and 56 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction in levels of plaque as measured by a plaque score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in inflammation</measure>
    <time_frame>14, 28, 42 and 56 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction in salivary cytokines IL-1, IL-6, IL-8, TNF-A, IL-12 and an increase in IL-10, and IL-13 as measured by immunofluorometric assay.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reduction in S. mutans</measure>
    <time_frame>14, 28, 42 and 56 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduced levels of S. mutans in plaque and saliva</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gingivitis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Lorodent (probiotic formulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorodent, at least 1 billion total CFU, taken once daily following tooth brushing in  a probiotic chewable lozenge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lozenge taken once daily after brushing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic formulation</intervention_name>
    <arm_group_label>Lorodent (probiotic formulation)</arm_group_label>
    <other_name>Lorodent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Have mild to moderate gingivitis as determined by dentist (GI of 1 or 2)

        Exclusion Criteria:

          -  Unable to make informed consent

          -  Subjects with allergies to milk or milk products, gluten or soy

          -  Immune compromised

          -  Major underlining medical condition

          -  Pregnancy

          -  Other oral disease such as existing periodontal disease, severe dental caries

          -  Recent or planned surgery of any kind (major or minor)

          -  ENT health problems

          -  Medications (antibiotics, anti-inflammatory) that can influence the outcome.

          -  Ongoing or recent (within 2 weeks) use of probiotics unrelated to the study

          -  Participation in a clinical trial within 30 days prior to randomization.

          -  Have within the past 30 days experienced any nausea, fever, vomiting, bloody diarrhea
             or severe abdominal pain
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Cadieux, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahza Hatibovic-Kofman, PhD, MDSc, DDS.</last_name>
    <role>Study Director</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carine Bourassa, DDS</last_name>
    <phone>(519) 661-2111</phone>
    <phone_ext>88851</phone_ext>
    <email>dr.cbourassa@live.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Western Ontario Orthodontics Clinic</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahza Hatibovic-Kofman, DDS, MDSc, PhD</last_name>
      <phone>(519) 661-4098</phone>
      <email>sahza.kofman@schulich.uwo.ca</email>
    </contact>
    <contact_backup>
      <last_name>Fernando Inocencio, DDS, MDSc</last_name>
      <phone>(519) 661-4067</phone>
      <email>inocencio@schulich.uwo.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 26, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Western Ontario, Canada</investigator_affiliation>
    <investigator_full_name>Peter Cadieux</investigator_full_name>
    <investigator_title>Adjunct Professor</investigator_title>
  </responsible_party>
  <keyword>gingivitis</keyword>
  <keyword>inflammation</keyword>
  <keyword>plaque</keyword>
  <keyword>orthodontics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gingivitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
